---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-028443"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2024-07-19T23:59:59+00:00"
generated_at: "2026-05-31T18:59:45.051478+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Daré regains Nasdaq minimum bid price compliance, delisting risk removed

## Summary
- Nasdaq notified Daré that closing bid price was ≥$1.00 for 10 consecutive sessions; compliance achieved.
- Regaining compliance avoids potential delisting from Nasdaq Capital Market, strengthening market position.
- Enrolling participants in pivotal Phase 3 study of Ovaprene for hormone-free monthly contraceptive candidate.
- Continuing activities to progress Sildenafil Cream 3.6% Phase 3 pivotal studies for female sexual arousal disorder.
- Awaiting additional FDA feedback on endpoints and safety database requirements for NDA submission.

## SEC filing metadata
- accession: 0001493152-24-028443
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2024-07-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000149315224028443/0001493152-24-028443-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000149315224028443/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-028443
- JSON: https://secwatch.observer/filing/0001493152-24-028443.json
- Plain text: https://secwatch.observer/filing/0001493152-24-028443.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.